t0901317 has been researched along with Prostatic-Neoplasms--Castration-Resistant* in 1 studies
1 other study(ies) available for t0901317 and Prostatic-Neoplasms--Castration-Resistant
| Article | Year |
|---|---|
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORĪ³ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
We report the design, optimization, and biological evaluation of nuclear receptor RORĪ³ inverse agonists as therapeutic agents for prostate cancer treatment. The most potent compound 27 (designated as XY101) exhibited cellular activity with an IC Topics: Acetanilides; Animals; Antineoplastic Agents; Binding Sites; Cell Proliferation; Drug Design; Drug Inverse Agonism; Gene Expression; Male; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Nuclear Receptor Subfamily 1, Group F, Member 3; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Rats; Structure-Activity Relationship; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |